Ken Griffin Kaleido Biosciences, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $633 - $21,533	-12,667 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.3 - $2.7 $28,182 - $58,533	-21,679 Reduced 63.12%	12,667 $21,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $6.02 $53,220 - $134,053	22,268 Added 184.37%	34,346 $82,000
Q3 2021 Nov 15, 2021	SELL	$5.36 - $7.99 $98,624 - $147,016	-18,400 Reduced 60.37%	12,078 $66,000
Q2 2021 Aug 16, 2021	BUY	$5.82 - $8.72 $68,937 - $103,288	11,845 Added 63.57%	30,478 $226,000
Q1 2021 May 17, 2021	BUY	$7.2 - $16.82 $134,157 - $313,407	18,633 New	18,633 $151,000
Q2 2020 Aug 14, 2020	SELL	$4.62 - $8.01 $79,741 - $138,252	-17,260 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.62 - $9.49 $28,214 - $73,965	-7,794 Reduced 31.11%	17,260 $106,000
Q4 2019 Feb 14, 2020	BUY	$5.02 - $8.87 $18,533 - $32,748	3,692 Added 17.28%	25,054 $126,000
Q3 2019 Nov 14, 2019	BUY	$6.74 - $11.3 $143,979 - $241,390	21,362 New	21,362 $160,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.